BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wedemeyer H, Khera T, Strunz B, Björkström NK. Reversal of Immunity After Clearance of Chronic HCV Infection-All Reset? Front Immunol 2020;11:571166. [PMID: 33133084 DOI: 10.3389/fimmu.2020.571166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Domovitz T, Gal-Tanamy M. Tracking Down the Epigenetic Footprint of HCV-Induced Hepatocarcinogenesis. J Clin Med 2021;10:551. [PMID: 33540858 DOI: 10.3390/jcm10030551] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Pisano MB, Giadans CG, Flichman DM, Ré VE, Preciado MV, Valva P. Viral hepatitis update: Progress and perspectives . World J Gastroenterol 2021; 27(26): 4018-4044 [PMID: 34326611 DOI: 10.3748/wjg.v27.i26.4018] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Brochado-Kith Ó, Martínez I, Berenguer J, González-García J, Salgüero S, Sepúlveda-Crespo D, Díez C, Hontañón V, Ibañez-Samaniego L, Pérez-Latorre L, Fernández-Rodríguez A, Ángeles Jiménez-Sousa M, Resino S. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients. Front Immunol 2021;12:723196. [PMID: 34497613 DOI: 10.3389/fimmu.2021.723196] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Soliman SHA, Orlacchio A, Verginelli F. Viral Manipulation of the Host Epigenome as a Driver of Virus-Induced Oncogenesis. Microorganisms 2021;9:1179. [PMID: 34070716 DOI: 10.3390/microorganisms9061179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Du Y, Khera T, Strunz B, Deterding K, Todt D, Woller N, Engelskircher SA, Hardtke S, Port K, Ponzetta A, Steinmann E, Cornberg M, Hengst J, Björkström NK, Wedemeyer H; HepNet Acute HCV Ⅳ Study Group. Imprint of unconventional T-cell response in acute hepatitis C persists despite successful early antiviral treatment. Eur J Immunol 2021. [PMID: 34843107 DOI: 10.1002/eji.202149457] [Reference Citation Analysis]
6 Sung PS, Shin EC. Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection. J Clin Med 2021;10:E221. [PMID: 33435135 DOI: 10.3390/jcm10020221] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Macek Jilkova Z, Saleem K, Afzal S, Decaens T. Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV. Livers 2021;1:313-21. [DOI: 10.3390/livers1040024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Khalil MA, Shousha HI, El-Nahaas SM, Negm MI, Kamal K, Madbouly NM. Depression in patients with chronic hepatitis-C treated with direct-acting antivirals: A real-world prospective observational study. J Affect Disord 2021;282:126-32. [PMID: 33412492 DOI: 10.1016/j.jad.2020.12.128] [Reference Citation Analysis]